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NeurogenesisAdenosine acts in parallel as a neuromodulator and as a homeostatic modulator in the central nervous system. Its
neuromodulatory role relies on a balanced activation of inhibitory A1 receptors (A1R) and facilitatory A2A receptors
(A2AR),mostly controlling excitatory glutamatergic synapses: A1R impose a tonic brake on excitatory transmission,
whereas A2AR are selectively engaged to promote synaptic plasticity phenomena. This neuromodulatory role of
adenosine is strikingly similar to the role of adenosine in the control of brain disorders; thus, A1R mostly act as a
hurdle that needs to be overcame to begin neurodegeneration and, accordingly, A1R only effectively control
neurodegeneration if activated in the temporal vicinity of brain insults; in contrast, the blockade of A2AR alleviates
the long-term burden of brain disorders in different neurodegenerative conditions such as ischemia, epilepsy,
Parkinson's or Alzheimer's disease and also seem to afford beneﬁts in some psychiatric conditions. In spite of this
qualitative agreement between neuromodulation and neuroprotection by A1R and A2AR, it is still unclear if the role
ofA1RandA2AR in the control of neuroprotection ismostlydue to the control of glutamatergic transmission, or if it is
instead due to the different homeostatic roles of these receptors relatedwith the control of metabolism, of neuron–
glia communication, of neuroinﬂammation, of neurogenesis or of the control of action of growth factors. In spite of
this current mechanistic uncertainty, it seems evident that targeting adenosine receptors might indeed constitute a
novel strategy to control the demise of different neurological andpsychiatric disorders. This article is part of a Special
Issue entitled: “Adenosine Receptors”.osine Receptors”.
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The role of adenosine as an extracellular signallingmolecule begun
with the seminal observations by Szent-Gyorgy on the ability of
purines to control the functioning of the heart [1]. This was later
followed by a series of studies carried out by Rob Berne relating
changes in the extracellular levels of adenosine with the function and
dysfunction of this same organ (reviewed in [2]). The discovery that
methylxanthines acted as antagonists of adenosine receptors [3]
represented a crucial step to establish the idea that adenosine indeed
acted as an extracellular signalling molecule operating selective
receptors. One such methylxanthine is caffeine, the most widely
consumed psychoactive drug worldwide, which was proposed to
mostly act as an antagonist of adenosine receptors [4]. Given that
caffeine mostly triggers phenotypic modiﬁcations related to brain
function [4], a major emphasis was directed towards a better
understanding of the role of adenosine receptors in the control of
synaptic transmission, which were ﬁrst described by Ginsborg and
Hirst [5].
2. Double role of adenosine as a neuromodulator and as
a homeostatic modulator
This short historical background is particularly important to stress
the dual role fulﬁlled by extracellular adenosine in the nervous system.
On one hand, as shall be detailed in the next section, adenosine has a
particular role as a neuromodulator, controlling the ﬂow of informa-
tion through neuronal circuits. This function is rather restricted to the
nervous system. However, it should always be kept in mind that
adenosine also fulﬁls another more general role in all eukaryotic cells
acting as a homeostatic modulator (see [6,7]). Thus, the extracellular
levels of adenosine convey paracrine signals designed to coordinate
metabolic activity in groups of cells forming a tissue, thereby allowing
a trans-cellular coordinated response to changes in the workload of
the tissue. This homeostatic regulatory role of adenosine also occurs in
brain tissue, where adenosine fulﬁls a double role of neuromodulation
as well as of homeostatic coordination and it is often difﬁcult to
disentangle both functions.
3. Effects of adenosine on brain function
Albeit there are four adenosine receptors (A1R, A2AR, A2BR and
A3R), the higher density of A1R and A2AR in the brain, together with
the generally modest impact on brain function of manipulations of
A2BR and A3R function, has led to the idea that the impact of
adenosine on brain function might mostly depend on the actions of
A1R and A2AR [8].
The most evident effect of adenosine in neuronal circuits of adult
mammals is to selectively depress excitatory transmission [9]. This
occurs through the activation of A1R, which are located both
presynaptically, postsynaptically and nonsynaptically [8]. This inhibi-
tion of excitatory, but not inhibitory [10–12], synaptic transmission is
mostly due to presynaptic A1R [11,13–16], in accordance with the
enrichment of A1R in synapses, mainly in excitatory synapses [17–19].
Themechanismof A1R-mediated inhibition of synaptic transmission is
considered to rely on the coupling of A1R to the inhibition of N-type
calcium channels (e.g. [20,21]) thus decreasing stimulus-evoked
release of glutamate in central synapses (e.g. [9,22]). However,
presynaptic A1R can also decrease miniature events in excitatory
synapses and this effect was proposed to depend on a direct ability of
presynaptic A1R to down-regulate the sensitivity of the release
apparatus [15,16,23,24]. When considering more integrative proper-
ties of neuronal circuits, it is likely that the role of postsynaptic and
nonsynaptic A1R might become of particular interest. Thus, A1R are
located in the postsynaptic density [17], where they can inﬂuence the
responsiveness to excitatory stimuli by a simultaneous control ofN-type calciumchannels andNMDA receptors [25,26]. A1R in neuronal
cells are also located nonsynaptically where they control potassium
current leading to neuronal hyperpolarization [27]. Finally A1R also
have non-neuronal localizations modulating both astrocytic and
microglia-related functions in brain tissue [28–30].
This prominent inhibitory role of adenosine in the control of ‘basal’
synaptic transmission (i.e. under conditions where synaptic plasticity
is not engaged) has largely clouded the effect of A2AR in the control of
brain function. This was further aggravated by the widespread idea
that the localization of A2AR in the brain was restricted to the basal
ganglia (e.g. [31]). Instead, A2AR are now recognised to display a
widespread distribution in the brain [8] and are mostly located in
synapses [32]. They seem to have limited impact on the control of
‘basal’ synaptic transmission but play a crucial role in controlling
synaptic plasticity (reviewed in [33]). Thus, presynaptic A2AR can
control the release of glutamate and play amajor role in shutting down
the profound A1R-mediated inhibition of synaptic transmission
[34,35], which would otherwise preclude the possibility of enhancing
synaptic efﬁciency upon increasing neuronal activity. Postsynaptic
A2AR can control NMDA receptors [36–38], which provides a
mechanistic basis to understand the observations that the pharma-
cological or genetic blockade of A2AR can attenuate long-term
potentiation at different excitatory synapses [37,39]. A particularity
of A2AR is their striking ability to undergo increases in expression and
density upon noxious conditions (reviewed in [40]), both in neurons
(e.g. [41]) aswell as in glial cells [42]. Accordingly, A2AR can affect glial
reactivity and control neuroinﬂammatory processes [43–47], in line
with the key role of A2AR as a STOP signal of the immune-
inﬂammatory system acting peripherally (reviewed in [48]). A2AR
are also located in endothelial cells of brain capillaries,where they play
an important role in controlling brain vascular function (reviewed in
[49,50]). The scope of action and effects of A2AR may be considerably
broader in view of their ability to heteromerise with different other G
protein-coupled receptors, such as dopamine D2, metabotropic
glutamate type 5 and cannabinoid CB1 receptors (for reviews see
e.g. [51,52]).
It is also important to mention that both A1R and A2AR [53–55], as
well as caffeine [56], can affect brain metabolism. It is still unclear to
what extent this metabolic control in brain tissue is related to the
neuromodulatory role of adenosine or represents a trait of the general
homeostatic role of adenosine observed in different types of
eukaryotic cells [57–60]. But this ability of adenosine receptors to
control metabolic activity is expected to play a potentially relevant
role in the control of both physiological and pathological brain
adaptive changes, which are highly dependent on adequate metabolic
support.4. Role of adenosine in different brain disorders
In view of the involvement of glutamate-associated excitotoxicity
in the aetiology of different brain disorders [61], the ability of
adenosine A1R and A2AR to control excitatory transmission prompts
considering this neuromodulation system as a putative therapeutic
target to manage brain disorders. This interest is further bolstered by
recurrent observations showing that the extracellular levels of
adenosine are modiﬁed upon brain damage. Thus, albeit the
extracellular levels of adenosine increase with neuronal activity
[62], they increase to considerable higher levels when brain damage
occurs [63]. This probably results from the increased use of ATP to
attempt preserving cell viability, which leads to a disproportionally
higher formation of adenosine (reviewed in [7]). Clearly, the
clariﬁcation of the metabolic and cellular sources of extracellular
adenosine is still unclear (discussed in [8]). However, the available
data consistently shows that noxious brain stimuli enhance the
extracellular levels of adenosine.
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By analogy with the pioneering studies of Berne's group in the
heart, hypoxic or ischemic conditions trigger a robust and sustained
enhancement of the extracellular levels of adenosine in the brain
parenchyma, in vitro brain preparations or cultured neurons (e.g.
[64,65], reviewed in [63]). A major interest was focused on the
potential role of A1R in the control of brain damage upon ischemia in
viewof the ability of theseA1R to control several events that have been
associated with ischemic damage, namely the control of calcium
inﬂux, the control of glutamate release, the control of membrane
potential and the control ofmetabolism (reviewed in [66–69]). Indeed
a role for A1R was conﬁrmed; thus, either A1R agonists or the use of
inhibitors of adenosine re-uptake or metabolisation (mainly through
adenosine kinase but also through adenosine deaminase) generally
tends to decrease the extent of ischemic brain damage ([70–73],
reviewed in [69]). In contrast, the blockade of A1R generally tends to
exacerbate ischemic brain damage (reviewed in [69]). However, these
manipulations are only effective if made in the immediate vicinity
(shortly, i.e. within circa 6 h, before or after the ischemic insult),
whereas chronic manipulation of A1R function caused paradoxical
effects [68,74].
This decreased function of brain A1R after ischemia is accompanied
by a decreased density of brain A1R after ischemia (e.g. [75–77]) and is
now thought to result from the desensitization of A1R; in fact, oxygen
deprivation causes a rapid down-regulation of A1R function, which is
dependent on the enhanced levels of adenosine and continuous
activation of A1R (e.g. [78–81]). However, this loss of function of A1R
after ischemic insults should not undermine the interest of A1R as a
potential therapeutic target in ischemic conditions. In fact, the group of
Detlev Boison provided exciting evidence supporting that an adequate
control of the adaptive changes of adenosine metabolism, through the
inhibition of adenosine kinase, could provide a novel strategy to
bolster a sustained A1R activation [82,83]. These studies clearly
illustrate that the adenosine modulation system should be seen as a
whole and studied as a whole, being senseless to attempt separating
the study of adenosine receptors from that of adenosine metabolism.
These studies also provide an in vivo conﬁrmation of the key role of the
A1R as a gate-keeper of neuronal damage, acting as a hurdle for the
initiation of brain damage upon noxious insults (discussed in [84]).
The idea that A1R might indeed be crucial to deﬁne the threshold of
sensitivity of the tissue to ischemic damage is further emphasised by
the observation that A1R play a key role in the cascade of events that
underlie ischemic preconditioning [85–88], the process by which a
sub- or near-threshold ischemic insult sets a cascade of events
(namely bolstering A1R function) that decreases damage to a
subsequent more intense insult. Clearly an aspect that remains to be
clariﬁed is the mechanism by which A1R might control the impact of
oxygen shortage on neuronal viability. Several groups directed their
efforts towards exploring if this neuroprotection was associated with
the function of synaptic A1R (e.g. [89–91]). However, the observation
that A1R also prevent ischemia-induced cytotoxicity in non-neuronal
tissues [57–60] might suggest that A1R-mediated control of ischemic
damage could involve amore general mechanism common to neurons
and other cell types.
Apart from this novel breath in the interest of indirectly
manipulating A1R function (through inhibition of adenosine kinase)
to control ischemic damage, most of the efforts are now being directed
to the exploitation of the role of A2AR in the control of ischemic brain
damage (reviewed in [40,92]). The involvement of A2AR in ischemic
brain damage was described nearly in parallel by the group of John
Phillis and that of Ennio Ongini at Schering-Plough; they ﬁrst found,
somehow serendipitously, that the blockade of A2AR afforded a robust
protection against ischemic brain damage [68,93–95]. This was later
conﬁrmed in experiments carried out by Jiang-Fan Chen, showing that
the genetic elimination of A2AR conferred a robust protection againstischemic brain damage [96]. Subsequently several studies in different
brain preparations indeed conﬁrmed that the pharmacological or
genetic blockade of A2AR consistently decreased the infarted area and/
or the outcome (neurological score) upon ischemic insults (see
references in [40,92,97]).
Although the available data is strikingly consistent in indicating an
important role for A2AR in the control of ischemia-induced brain
damage, there are still several open questions before attempting any
translational application of this idea. In fact, it still remains to be
explored what is the time window of opportunity for the manipula-
tion of A2AR, namely if blocking A2AR might solely be considered a
prophylactic strategy or if it might also have some therapeutic
potential (see discussion in [98]). Also, the clariﬁcation of the
mechanisms underlying this ability of A2AR to control ischemia-
induced neuronal damage should be tackled to ensure a sustained
translational rationale; in fact, different manipulations in animal
models have supported the possible participation of different
mechanisms, either controlling glutamate release [99,100], central
inﬂammatory processes and glial reactivity [42,101,102] or the
permeability of the blood-brain barrier [103,104] and inﬁltration of
peripheral myeloid cells [105]. However, the recent pioneering
studies showing that caffeinol improves stroke recovery [106], as
well as post-traumatic injury [107] are certainly an exciting (albeit
certainly indirect) suggestion prompting further investigation of the
potential therapeutic effects of A2AR blockade to manage the post-
ischemic recovery of brain function.
4.2. Epilepsy
Epilepsy corresponds to a series of disturbances of neuronal ﬁring,
often accompanied by bursting encephalographic activity with the
appearance of paroxysmal depolarisation shifts [108]. Seizures have
traditionally been viewed as an imbalance between excitatory and
inhibitory transmission in brain circuits, where hyper-excitation or
hypo-inhibitionwould result in an abnormal repetitive ﬁring of affected
brain circuits [109]. The potential of adenosine as an anti-epileptic
substance [84,110–113] has emerged on the basis of two parallel
observations: ﬁrst, A1R are enriched in excitatory synapses, where they
inhibit glutamate release, decrease glutamatergic responsiveness and
hyperpolarise neurons, all desirable actions to decrease the hyper-
excitability associated with epilepsy; second, the levels of endogenous
extracellular adenosine rise upon seizure activity [114,115], which
could be taken as an indication that adenosine would play a key role as
an endogenous anti-epileptic compound. Accordingly, a wealth of
studies have conﬁrmed that the acute administration of either agents
enhancing the extracellular levels of adenosine (inhibitors of adenosine
transporters or of adenosinemetabolism) or agonists of A1R attenuated
seizure and/or convulsive activity in different animal models;
conversely, the acute administration of either non-selective antagonists
of adenosine receptors (such as caffeine or theophylline) or selective
A1R antagonists enhance the duration and severity of seizures and/or
convulsions (reviewed in [84,110–113]). Thus, it seems evident that
A1R effectively constitute a hurdle curtailing seizure activity, which is
further conﬁrmed by the ability of A1R to control the spreading of
seizure activity [116] and the greater susceptibility of A1R knockout
mice to epilepsy [116–118]. Interestingly, this A1R-mediated control of
epilepsy has recently been proposed to be a possible link for the anti-
epileptic effect of ketogenic diets [119].
However, several studieshavenowidentiﬁedadecreaseddensity and
efﬁciency of synaptic A1R in models of epilepsy [17,18,120–122]. Thus,
the A1R-operated inhibitory system seems to act as a continuously active
gate-keeper or hurdle to avoid initiating a seizure-like event; once this
hurdle is overtaken, then there is a desensitization of this A1R system.
Furthermore, the long-term consumption of moderate doses of caffeine
(0.3 g/L) was found to prevent neuronal damage in different models of
epilepsy [123–125]. Thus, in spite of the ability of chronic caffeine
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blockade of adenosine receptors by caffeine reveals a beneﬁcial effect on
seizure-induced neuronal damage. These observations prompt two
conclusions. First, there seems to be a clear dissociation between the
ability of A1R to control glutamatergic transmission and to control other
features present in epilepsy, which was directly documented in the case
of pilocarpine-induced seizures [127,128]. Secondly, there is a suggestion
that, probably, the greatest contributing factor for decreased function of
the endogenous A1R-mediated inhibitory system might be the lack of
adequate adenosine receptor tonus, which might be a result of the
modiﬁed purinergicmetabolism [82,113], namely a long-term reduction
of the extracellular levels of adenosine [17], due to the robust increase of
the expression and activity of ADKmainly in astrocytes [129,130], which
seems to be a key event in the re-adaptation of the adenosinergic system
[113]. Thus, albeit there is a decrease in the density of presynaptic A1R,
their activationmaystill be anattractive andeffectivemanner to restraint
subsequent seizure activity in model of chronic ‘epilepsy,’ as testiﬁed by
robust evidence showing that A1R are still able to efﬁciently control
chronic epileptic-like conditions [113] and even pharmaco-resistant
forms of epilepsy [131]; this might be better achieved by manipulating
ADK rather than directly activating A1R using A1R agonists since the
latter have profound cardiovascular peripheral effects (e.g. [132]).
Interestingly, since ADK seems to be mostly an astrocytic enzyme in
theadult anddiseased brain [113], this consideration of ADK inhibitors as
novel candidate anti-epileptic drugs clearly shifts the main focus of
epilepsy from neurons to astrocytes (reviewed in [84,133]).
As occurred for ischemia-induced neuronal dysfunction and damage,
an increasingnumber of studies on adenosinemodulation of epilepsy are
now shifting their focus from the better characterized inhibitory A1R
system, to concentrate on the possible role of facilitatory A2AR in the
control of epilepsy (reviewed in [84]). Interestingly, upon chronic
epilepsy there is a robust increase (over 200%) of the density of A2AR
[18]. Albeit the impact of A2AR on the onset of seizure activity is still
disputable (reviewed in [84,112]), recent elegant studiesmake it evident
that the blockade of A2AR, either using genetic deletion of A2AR or
selective A2AR antagonists [134–136] or non-selective antagonists such
as chronic caffeine administration [134] can afford a robust protection
against the seizure evolving severity. Furthermore, chronic caffeine
administration or A2AR blockade effectively prevents neuronal damage
following convulsions [123–125,137] and seems to be a general indicator
of favorable prognosis in diseases involving neurodegeneration
[138,139]. Thus, A2AR seem to control the evolution and consequences
of seizures, both seizure-beget-seizure and seizure-induced neurode-
generation, although the mechanisms involved (glial or neuronal) still
remain to be clariﬁed (reviewed in [40,84,92]). Interestingly, the source
of the adenosine proposed to preferentially activate A2AR (ATP-derived
adenosine formed through the ecto-nucleotidase pathway; reviewed in
[7,140,141]) is also modiﬁed in ‘epileptic’ rodents; thus, there is a lower
release of ATP and a modiﬁed extracellular catabolism of ATP
[17,142–145], but more importantly, there is an augmentation of the
density and activity of ecto-5′-nucleotidase [17,144–147], which is often
the rate-limiting step in the formation of adenosine from extracellular
ATP [140,148]. Thus, there seems to be anupregulation of A2ARaswell as
of the source of adenosine activating them and A2AR blockade seems to
afford beneﬁcial effects in animal models of epilepsy.
4.3. Huntington's disease
Huntington's disease (HD) is an inherited neurodegenerative
disorder caused by a mutation of the gene which encodes for the
protein huntingtin [149]. Normal huntingtin, whose function is not
completely known, is associated with vesicular membranes, micro-
tubules and several proteins involved in synaptic function [150,151],
suggesting that mutated huntingtin likely alters synaptic transmission
in HD [152,153]. Several studies support the original idea of Wong and
coworkers [154] that cortico-striatal glutamatergic deregulation shouldbe involved in HD pathogeny. Indeed, mutated huntingtin induces
glutamatergic dysfunctions, namely: i) increases glutamate release and
decreases astrocytic glutamate clearance [155,156]; ii) increases
expression and activation of NMDA receptors (for a review see [157]);
iii) induces changes in NMDA receptor subunits [158–160]; and iv)
triggers mitochondrial dysfunctions secondary to glutamate-induced
toxicity or impaired energy metabolism [161,162], among others.
This major deregulation of this cortico-thalamic afferent glutamater-
gic input would be the primary cause of the hallmark of HD, which is the
degeneration of the major striatal neuronal population, the GABAergic
medium-sized spinyneurons (MSNs).MSNs aredivided into twodistinct
classes based on different anatomical and pharmacological criteria, as
well as by the segregation of adenosine and dopamine receptors:
dynorphinergic MSNs co-expressing A1R and dopamine D1 receptors
and enkephalinergic MSNs co-expressing A2AR and dopamine D2
receptors. Both MSN sub-classes are driven by cortico-thalamic gluta-
matergic excitatory inputs and their relative responsiveness is controlled
by dopaminergic inputs from the substantia nigra pars compacta (SNc)
[163],which determines the subsequent control ofmotor function.MSNs
constantly receive inputs from cortical glutamatergic terminals, but
remain hyperpolarized by mechanisms such as presynaptic inhibitory
modulation in glutamatergic terminals, operated by A1R, D2 or GABA-B
receptors among others [164–169] and postsynaptic inwardly rectifying
K+ channels [170], both preventing depolarization. Continued exposure
to glutamate and persistent opening of NMDA channels, make MSNs
vulnerable to excitotoxic damage. As deregulation of glutamate
transmission occurs, morphologic and functional (plastic) synaptic
changes take place, namely a down-regulation of inhibitory presynaptic
receptors and a decrease of the area of the soma, dendrites and dendritic
spines ofMSNs (for a review see [171]); these changes have an impact on
the number of functional K+ channels responsible for the hyper-
polarization of MSNs. Altogether, the referred changes contribute to
depolarization at rest and ampliﬁcation of excitatory inputs. Further-
more, as the postsynaptic area decreases, extrasynaptic receptors, which
often display different functional properties from synaptic ones, become
prominent. This is the case for NMDA receptors, which extrasynaptically
worsen cell dysfunction eventually causing death [172].
The striatum is particularly rich in A1R and A2AR. Notably, the
striatum has the highest density of A2AR in the brain [173,174], which
supports the pathophysiologic relevance of A2AR in motor diseases.
A2AR can be found presynaptically on the cortico-striatal glutamatergic
afferents [175], where they modulate glutamate release [35,176], but
are mainly located postsynaptically in MSNs [173]. Besides neurons,
A2AR are also present in non-neuronal cells, such as endothelial and
glial cells which allow a control of vasodilation and glial responses to
injury and inﬂammation [177–179]. Several lines of evidence point
towards a pathophysiologic role for adenosine A2AR in HD: 1) changes
inA2ARgene, expression, density and signaling; 2) early vulnerability of
MSNs selectively expressing A2AR; 3) physiologic role of A2AR inmotor
control; 4) ability of A2AR to control glutamatergic transmission;
5) A2AR involvement in neuroinﬂammation; 6) A2AR ability to regulate
metabolism and mitochondrial functioning.
In spite of some controversy mainly due to observations in distinct
animal models of HD (e.g. genetic versus toxin-induced models),
differentphases of the “disease,” (pre-symptomatic versus symptomatic
periods), most animal studies point towards changes in A2AR
expression, density and/or signaling [180–183]. Moreover, recent
evidence indicates that a polymorphism of the A2AR gene (ADORA2A)
can inﬂuence the age of onset of HD patients [184]. As stated above,
continued exposure to glutamate and persistent opening of NMDA
channels, make MSNs vulnerable to excitotoxic damage, in particular
those expressing A2AR, which receive more glutamatergic inputs from
the cortex [185], further supporting a role for A2AR in HD physio-
pathology. Furthermore, the hyperkinetic phenotype of the disease
seems to be due to the early loss of A2AR-expressing MSNs.
Neuroprotective effects attributed to A2AR antagonists correlate well
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its release [188,189] or decreasing its release and enhancing its uptake
by glial cells [190–193]. A2AR in glutamatergic synapses are also able to
control the activation/expression of NMDA receptors [194,195], their
subunit composition [196] and plastic changes in cortical glutamatergic
inputs [174].
Whereas the presynaptic role of A2AR antagonists is increasingly
accepted as neuroprotective, an effect mainly attributed to the
modulation of glutamatergic transmission, the postsynaptic and
extrasynaptic effects of A2AR blockade have been speculative and
most studies favor A2AR agonists, rather than antagonists as
protective agents in the particular case of the degeneration of MSNs.
These results were attributed to the ability of A2AR antagonists to
potentiate NMDA-mediated toxicity and to the ability of agonists to
reduce NMDA currents in striatal MSNs [188,189,194,197,198].
The same controversy exists regarding metabolic compromise and
mitochondrial dysfunction secondary to excitotoxicity in HD, where
A2AR antagonists or genetic blockade of the receptor has been shown to
be either protect or increase striatal MSN lesion [199–201]. The
controversy further increases when considering that the compromise
of the cortico-striatal pathway determines a decrease in the supply of
trophic factors to the striatum, in particular brain-derived neurotrophic
factor (BDNF), which plays an important role in the pathophysiology of
HD [202]. It is well known that the ability of A2AR agonists can
transactive the TrkB BDNF receptor, and are also able to regulate levels
and effects of different neurotrophic factors, including BDNF [203].
Thesemodulatory actionsmay be beneﬁcial in terms of trophic support
to degenerating neurons. However, BDNF exerts multiple cellular
functions, including the potentiation of glutamate release [204] and
sustaining neuroinﬂammation [43]. According to these observations
and to the dual effects of BDNF, dependent on the activation of different
receptors (p75versusTrkB, see below), it is important to emphasize that
trophic factors are not always “good” players in the neurodegenerative
course of diseases. Thus, the enhancement of BDNF-mediated effects by
A2AR agonistsmay also have deleterious effects. Finally, A2AR blockade
is generally accepted as a protective strategy in the control of
neuroinﬂammation in several degenerative conditions, including HD.
However, the relative importance of A2AR-mediated contention of
inﬂammation, in particular its in vivo relevance, still requires further
investigation.
In conclusion, in spite of the established pathophysiologic role of
A2AR inHD, it remains to be clariﬁed if it is the activation or theblockade
of A2AR that can bring about clinical beneﬁts. The complexity of
functions operated by A2AR in speciﬁc cellular and regional locations
speciﬁcally in the striatum may suggest that neither stimulation nor
blockade are beneﬁcial or that both can be advantageous, depending on
the time-frame of the disease taken into account. Thus, HD is a special
case of a brain disorder where both A2AR agonists and antagonists have
been shown to provide protection in animal models of HD.
4.4. Parkinson' disease
The etiology of Parkinson's disease (PD) is still ill-deﬁned, in spite
of the established inﬂuence of genetic and environmental factors.
Independently of the trigger, protein misfolding and aggregation and
mitochondrial dysfunction associated oxidative stress are important
in PD pathogenesis (for a review see [205]). The pathologic hallmark
of PD is the loss of dopamine innervation in the striatum and the
subsequent degeneration of dopaminergic neurons from the SNc,
even though the degenerative process extends beyond dopaminergic
neurons [206]. Dopamine depletion attenuates the control of striatal
circuits and, in particular, reduces the inhibitory tonus to MSNs
selectively expressing A2AR [207], which characteristically become
overactive. To balance early changes in inhibitory dopaminergic
tonus, compensatory mechanisms, such as plastic adaptations in the
cortico-striatal pathway [208–210], probably delaymotor impairmentand justify the existence of a pre-symptomatic period [211] preceding
the gradual appearance of symptoms.
As occurs in HD, strong evidence highlights the critical role of
A2AR in the pathophysiology of PD, namely: 1) the physiological role
of A2AR in motor control; 2) the ability of A2AR to control
glutamatergic transmission; 3) the increased A2AR-mediated activity
in PD; 4) the eventual A2AR involvement in neuroinﬂammation,
which is most evident in the substantia nigra; 5) the ability of A2AR to
regulate metabolism andmitochondrial functioning. In contrast to the
controversy around A2AR manipulation as a therapeutic approach in
HD, A2AR antagonists are currently under clinical trials in PD patients,
given their ability to control motor impairment and to confer
neuroprotection, as suggested by the epidemiologic inverse relation
between the consumption of caffeine (an antagonist of adenosine
receptors) and the risk of developing PD [212,213].
Adenosine control of motor function is centered on the ability of
A2AR to tightly control dopamineD2 receptor function, both at the level
of intracellular signalling aswell as by the formation of heteromerswith
D2 receptors (reviewed in [174], although these receptors form
heteromers with different receptors, also functionally important in
striatal physiology (see [214]). In fact, almost 20 years after the
observation that adenosine receptor antagonists exert the same motor
effects as dopamine receptor agonists (i.e. hyperlocomotion, see [215]),
it was discovered that A2AR and D2 receptors co-localize [216–218],
form heteromers [219,220] and alter each other's pharmacological
properties such as afﬁnity and desensitization [218,221]. A2AR and D2
receptors have antagonistic interactions not only at themembrane level
but also at the intracellular signalling (reviewed in [174,222]). Thus, the
net result of dopamine depletion in the striatum is an A2AR over-
signalling resulting in typical hypokinetic symptomsof PD and blockade
of A2AR became an attractive alternative (or adjunctive) to the
dopamine-based therapeutic approaches.
A2AR antagonists improve motor function in different rodent and
primatemodels of PD, aloneor co-administeredwith dopaminomimetic
drugs, levodopa or dopamine agonists [223–227]. When administered
after the onset of the most severe side-effect of levodopa, dyskinesia,
A2AR antagonists have an additive beneﬁcial effect upon motor
disability and do not worsen dyskinesia [224,228–231]. These non-
clinical studies culminated in clinical trials testing the A2AR antagonist
istradefylline (KW-6002) in PD patients. There is only one inconclusive
clinical report showing that istradefylline alone had no effect on motor
dysfunction [232]. However, istradefylline co-administered with low
doses of levodopa potentiates motor improvement, without worsening
dyskinesia [233]. Further clinical studies involving patients in low-dose
levodopa therapeutic schemes are needed in order to clarify the
adjunctive potential of A2AR antagonists, since most results were
assessed in patients under optimal levodopa doses and may underes-
timate the therapeutic potential of A2AR antagonists (for a review see
[234]).
Currently, ﬁrst line pharmacotherapeutical strategy in PD aims at
restoring dopamine levels and/or effects, by the use of a dopamine
precursor, dopamine agonists and inhibitors of enzymatic degradation
of dopamine. These drugs, which mainly interfere with motor
symptoms, have, at least, two limitations: long-term side-effects (in
particular, motor disability, including dyskinesia) and inability to stop
the ongoing degenerative process. In this regard, A2AR pharmacological
or genetic blockade reduce dopaminergic cell loss and counteract
striatal dopamine depletion, underpinning an effective neuroprotective
role for A2AR,whichmechanismhas not yet been ascertained, but seem
to be different from that mediating motor effects of these ligands
[235–237]. As stated above, abnormal glutamatergic transmission may
be implicated in PD pathogeny. Accordingly, the neuroprotective role
attributed toA2ARblockade is also basedon the ability of the receptor to
increased glutamate release [7,174,188]. It was also suggested that
neuroprotection by the A2AR antagonists may be related with the
inhibition of glial activation [237] or with the inhibition of dopamine
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antagonism in PD likely results from the balance between a plethora of
effects, which deserves detailed integrative analysis in order to clarify
the clinical applicability of receptor manipulation.
4.5. Alzheimer's disease
Alzheimer's disease (AD) is the most common neurodegenerative
disorder that affects the elderly. In fact, advanced age is the major risk
factor for AD, as its incidence is around 1–2% in peoplewith 60–64 years
old, rising to about 30% in those aged 85 years old and older [239,240];
thus the increase of life-expectancy is transforming AD into a great
health-care problem.AD is characterizedbyaprogressive impairmentof
memory and other cognitive skills leading to dementia [240,241]. The
neuropathological hallmarks of AD include (in order of relevance):
i) selective synaptic andneuronal loss in several brain regions, including
the cerebral cortex and hippocampus; ii) senile plaques, mainly
composed of amyloid-β peptide (Aβ); iii) neuroﬁbrillary tangles
[242,243]. Currently, it is accepted that AD pathogenesis results from
the imbalance between production and clearance of Aβ, which derives
from the abnormal processing of the amyloid precursor protein (APP) at
the β-secretase (BACE 1) and γ-secretase sites to produce Aβ fragments
of 40 or 42 amino acids [244,245].Moreover, the Aβ cascade hypothesis,
postulates that soluble Aβ oligomers (particularly 12-mers), rather than
the ﬁbrillar forms, are responsible for the synaptic dysfunction and loss
that underlie early memory impairment in AD [242,246]. Aβ oligomers
build up into proto-ﬁbrils and ﬁbrils, giving rise to diffuse plaques that
may evolve to neuritic plaques, also named senile plaques, which often
have a dense amyloid core and are associated with clusters of activated
glia cells (microglia and astrocytes) and dystrophic neuronal processes
[243,247]. Synaptic degeneration, which is detectable already in
patients with mild cognitive impairment (a prodromal state of AD),
progresses during the course of AD [241,248] and in most early stages
involves mechanisms of compensation before reaching a stage of
decompensated function [249]. Synaptic dysfunction and loss in cortical
regions, mainly in the neocortex and hippocampus, is an early change
and the major structural correlate of cognitive deﬁcits in AD, as
supported by a variety of electron microscopic, immunocytochemical
and biochemical studies on synaptic proteins markers in biopsies and
autopsies of brain's patients (reviewed in [249]).
Adenosine, mainly through its action on A1R and A2AR, can control
and integrate cognition and memory [250]. In the brain, A1R and A2AR
are mainly located in synapses, controlling the release of neurotrans-
mitters, suchas glutamate andacetylcholine that are involved inmemory
and other cognitive processes [40,251]. Increasing evidence suggest that
adenosine receptors change their pattern of localization and density in
afﬂicted brain regions of AD [250]; however, the role of adenosine and its
receptors in regulating the pathogenesis of this neurodegenerative
disease remained weakly known. Post-mortem analysis of frontal cortex
of AD patients showed that the total number (assessed by binding
studies) and levels (determined by Western blot analysis) of A1R and
A2AR are signiﬁcantly increased in either early or advanced stages of this
disease [252].Moreover, a re-distribution of these receptorswas found in
the hippocampus and cortex of AD patients, such as an increased A1R
immunoreactivity in neurons with neuroﬁbrillary tangles and/or in
dystrophic neurites of senile plaques and anupregulation of A2AR in glial
cells [253]; however, the level of transcriptionof theA1Rgene (measured
byquantitative PCR)was similar in control andADbrain [253]. This study
also analysed if other metabotropic receptors undergo changes in their
cellular localization in the AD brain and found that no signiﬁcant change
was evident for several other metabotropic glutamate receptors [253];
this suggests that the re-distribution of adenosine receptors in AD brain
may be a speciﬁc and relevant event. Furthermore, in a transgenic mice
model of AD carrying the APP Swedish mutation (APPSw), it was also
reported that the levels of A1R and A2AR are augmented as compared
with non-transgenic mice [254]. However, it must be referred thatautoradiography and binding studies performed in the 1990s showed
that the density of A1R was reduced in the hippocampus of AD patients
[255–257] and a loss of A1R was also observed in the hippocampus of
patients with sclerosis-associated dementia [257]. A recent study using
positron emission tomography (PET) and 8-dicyclopropylmethyl-1-[11C]
methyl-3-propylxanthine showed a signiﬁcant reduction in A1R binding
potential in the temporal cortex and thalamus of AD patients as
compared with elderly normal subjects [258]. This reduction in the
density of A1R is in agreement with the decrease of A1R density and
efﬁciency in neurodegenerative disorder (reviewed in [40]).
Chronic stressful brain conditions also trigger the upregulation of
A2AR, prompting the hypothesis that the manipulation of these
excitatory receptors may control neurodegeneration [40]. Accordingly,
numerous studies show that the modulation of A2AR could have
neuroprotective effects in AD. Studies in vitro showed that A2AR
antagonism prevents synaptic loss as well as neuronal death triggered
by Aβ synthetic peptides [259,260]. However, the mechanisms of
neuroprotection by A2AR antagonism against Aβ still remain to be fully
characterized. It is known that A2AR can control the neurochemical
consequences of enhanced production of free radicals [261,262] and
glutamate excitotoxicity [40] and that adenosine receptors can affect
neuronal primary metabolism [54,55], albeit the exact impact of the
different adenosine receptor subtypes on astrocytic and neuronal
metabolism remains to be established. This ability of A2AR to control
mechanisms involved synaptic degeneration and subsequent neuronal
death opens the possibility thatA2AR antagonistsmight actually control
this apparently reversible synaptic dysfunction (reviewed in [250]),
which might be an effective strategy to arrest neurodegenerative
diseases at their early stages before they evolve into overt irreversible
neuronal loss [263].
Beneﬁts for cognitive deﬁcits in AD patients and AD animal models
might be achieved by manipulating A2AR, since these receptors
facilitate the synaptic mechanisms of memory and learning [250,264].
Some of the strongest evidence rely on the impact in different AD
animal models of caffeine (the most widely consumed behavioral
stimulant presentmainly in coffee and tea), which, in non-toxic doses,
acts as an antagonist of adenosine receptors, mainly of adenosine A1R
and A2AR [4]. Maia and de Mendonça reported the ﬁst retrospective
epidemiological data showing that the incidence of AD was inversely
associated with the consumption of coffee in the previous two
decades of life [265]. An inverse relation between caffeine intake and
age-related cognitive impairment was also noted in three other
epidemiological studies [266–268]. Finally, a recent study also shows
that coffee drinking at midlife is associated with a decreased risk of
dementia/AD later in life [269]. A different drug, propentofylline,
which acts as a mixed blocker of nucleoside transporters and of
adenosine receptors [270], was also reported to afford beneﬁcial
effects on cognition, but not on activities of daily living, in patients
with vascular dementia [271]. This evidence from human studies is
concurred by results obtained in animal models of aging and AD; thus,
there is evidence for a beneﬁcial role of caffeine and/or selective A2AR
antagonists in animal models of aging [272,273] and AD
[141,254,259,274,275]. In AD transgenic mice (APPsw), a 6-month
period of caffeine intake (0.3 g/L) alleviated the cognitive deﬁcits
found in these mice, and restored the levels of soluble Aβ [254].
Furthermore, in cultured neurons from these AD mice, caffeine also
reduced the production of Aβ1–40 and Aβ1–42 peptides [254], whereas
propentofylline attenuated tau phosphorylation [276]. Likewise, acute
caffeine administration to both young adult and aged AD transgenic
mice rapidly reduces Aβ levels in both brain interstitial ﬂuid and
plasma, whereas long-term oral caffeine treatment to aged AD mice
provided not only sustained reductions in plasma Aβ, but also
decreases in both soluble and deposited Aβ in hippocampus and
cortex [277]. Delayed memory deﬁcits caused by intracerebral
administration of Aβ were prevented by either caffeine or selective
A2AR antagonists [33,259,275]. Moreover, it was shown that, in A2AR
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cause cognitive deﬁcits or synaptotoxicity [259]. Although it was
reported that A1R density is increased in afﬂicted brain regions of AD
patients [252,253] and that A1R can also control the production of
soluble Aβ in vitro [253], the protective effects of caffeine in AD animal
models are not mimicked by antagonists of A1R but rather by
antagonists of A2AR [33,259,260,275]. These data further strength the
idea that caffeine affords a prophylactic beneﬁt on memory
performance through its action on A2AR, which were found to be
upregulated in cortical regions both in AD animals models [254] and
AD patients [252,253]. A recent study also found that caffeine might
actually be able to revert the pre-installed working memory deﬁcits
and the pre-existing considerable Aβ burden in aged AD transgenic
(APPSw) mice [274]. Caffeine and/or the selective blockade of A2AR
are also effective in reverting other experimental conditions of
mnemonic impairment (reviewed in [250]). In fact, our group recently
reported that a single convulsive episode in the early life of rats causes
a delayed memory deﬁcit in adulthood accompanied by a glutama-
tergic synaptotoxicity that was prevented by caffeine or A2AR
antagonists [278]. Likewise, caffeine also prevented both the memory
impairment as well as the loss of synaptic markers caused by an
experimental model of diabetes [56]. The chronic use of a low dose of
caffeine also prevents short-term memory deﬁcits and early long-
term potentiation in acutely (24 h) sleep-deprived rats [279]. The
memory impairment and synaptotoxicity associated caused by a
protocol of chronic unpredictable stress were also prevented by either
chronic caffeine consumption or A2AR antagonists or genetic deletion
of A2AR [280]. In both rodents and humans, the acute memory
impairment caused by the administration of scopolamine (an
antagonist of cholinergic muscarinic receptors) was found to be
prevented by caffeine [281,282], prompting the hypothesis that
adenosine receptors might also correct cholinergic hypofunction
associated with memory impairment (but see [283]).
Taken together, the above discussed evidence strength the idea
that both caffeine and A2AR antagonists can act as a cognitive
normaliser, rather than as a cognitive enhancer, and thus the blockade
A2AR may be a novel promising prophylactic and/or therapeutic
option to manage the precocious phases (synaptic loss and cognitive
impairment) of AD (reviewed in [250]). Furthermore, the ability of
caffeine and A2AR antagonists to control memory dysfunction under
different pathological conditions indicates that A2AR may impact on
memory preservation in general rather than affecting selectively
pathogenic mechanisms of AD. However, our knowledge about the
role of adenosinergic system, mainly of adenosine receptors¸ in AD
pathogenesis and associated memory loss still needs to be detailed to
afford a better understanding of the therapeutical potential of the
adenosine neuromodulation system in AD (discussed in [98]).4.6. Depression
Depressive disorders are frequent forms of psychiatric conditions
estimated to become the second leading cause of disability by the year
2020 [284]. The difﬁculty to understand the neurobiological basis of
depressive disorders, together with the inadequacy of currently
available treatments, contributes to the signiﬁcant health burden
associated with this disease (reviewed in [285]). In the past three
decades, systematic epidemiological studies have highlighted a
relationship between caffeine intake and speciﬁc psychiatric symptoms
(reviewed by [33,286]). These data are the strongest piece of evidence
linking the adenosinergic system inmodulation of mood, since caffeine,
at non-toxic doses, acts as an antagonist of A1R and A2AR [4,287].
However, studies trying to clarify the mechanisms underlying antide-
pressant action and animal models designed to unravel the neurobio-
logical basis of depression also point to a role for adenosine receptors in
the regulation of mood.Caffeine intake is so common, in different time-schedules and
different doses, that is difﬁcult to determine, from the epidemiological
point of view, how it affects the evolution of psychiatric disorders. The
literature is complex, with both positive [267,288–290] and negative
[291–293] effects being suggested. The consumption of low to
moderate doses (b6 cups/day) is well known to increase energy and
attention and to decrease cognitive failures (reviewed in [264]),
depressive symptoms and risk of suicide [267,294]. However, in large
amounts, caffeine can act as a trigger of psychiatric symptoms, from
anxiety to depression and even psychosis in both normal and
vulnerable subjects [295]. Conversely, a variety of mood related
symptoms are also triggered upon withdrawal from regular caffeine
consumption, including anxiety, irritability, sleepiness, dysphoria,
nervousness or restlessness [296–300]. More recently, compromised
adenosine transport due to variation in nucleoside transporter gene
SLC29A3 was suggested to enhance susceptibility to depression in
women [301].
The effect of the adenosine neuromodulation system in depression
is complex, especially due to its ability to modulate several other
neurotransmission systems, such as dopaminergic, glutamatergic and
serotoninergic as well as the corticotrophin system [302–306].
Adenosine and its analogues were shown to cause a depressant-like
response in behavioral despair models [307–309], an effect that was
prevented by the administration of classical antidepressants [310]. In
contrast, other studies showed an antidepressant effect associated
with adenosine administrated both systemically and centrally
[311–313].
The strongest evidence supporting the relation between adenosine
anddepression in preclinicalmodels came frommanipulation of A2AR.
Available data suggests that A2AR antagonists might be novel
antidepressants compounds (reviewed in [141]). The main evidence
sustaining this hypothesis relies on the observation that the genetic
depletion of A2AR results in an antidepressant-like phenotype in
animalmodels [314,315]. In addition, A2AR blockade relieves the early
hippocampal modiﬁcations induced by stress [316], one of the major
environmental factors favoring the implementation of depressive
states [317].
It is important to highlight that different therapeutic strategies
currently used tomanage depressive disorders also have effects related
to the adenosine system. Tricyclic antidepressants such as nortriptiline,
chlorimipramine or desipramine can bind to adenosine receptors [318]
and dose-dependently reduce the activity of ecto-nucleotidases and,
expectedly, the levels of extracellular adenosine in cortical synapses
[319]. In addition, both electroconvulsive therapy and sleep deprivation
cause an increase of adenosine concentration and of A1R activation [28].
In conclusion, although at this stage the relationbetween adenosine and
depression is still circumstantial, it seemsevident that theadenosinergic
system is able tomodulate mood states by functioning as a normalizing
system, and both too high or too low levels of activation can cause a
failure in the organism to adapt and a predisposition to disease [320].4.7. Bipolar disorders
The ﬁrst account for a purinergic dysfunction in bipolar disorders
can be attributed to Kraeplin (1921) when exploring the association
between manic symptoms and purinergic metabolism (uric acid
excretion, hyperuricemia and gout) [321]. Later, an increased
excretion of uric acid during initial phase of remission from manic
episode and an enhanced purinergic turnover was observed during
mania [322]. The efﬁcacy of the xanthine oxidase inhibitor allopurinol
to improve patientswithmania seems to support that a dysfunction of
the purinergic systemmight be associatedwith this disease [323,324].
In addition, historical reports describe that lithium, an effective
antimanic agent, was primarily used to treat disorders related to a
dysfunction in purinergic metabolism (gouty diseases) [325].
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kindling phenomena, a valuable model to explain the pathological
activation, increase of energy and recurrence of maniac episodes,
typical components of the bipolar illness (reviewed in [326]). The
kindling phenomena stimulate the release of adenosine and adenosine
receptor agonists have anti-kindling properties, attributed to the
activation of A1R [327]. Caffeine and aminophyline (two non-selective
adenosine receptor antagonists) have ‘mania-like’ stimulant effects
and signiﬁcantly increase kindled seizure duration and induce a
persistent state of arousal [328,329]. Caffeine also seems to exacerbate
manic symptoms [330] and heavy caffeine intake appears to
contribute to worsen the course of seasonal bipolar disorder [331].
The convulsive behavior in kindled rats was also demonstrated to
cause a long-term decrease of A1R density accompanied by an
increased density of A2AR in the cortex and hippocampus [17,18].
The decrease of A1R functioning has been associated with an increase
in intracellular cAMP levels, GS proteins expression, calcium inﬂuxes
and protein kinase C activation and all these abnormalities in second
messenger systems and intracellular pathways are also relevant
signals associated with bipolar disorders (reviewed by [332]). In
contrast, the role of A2AR in psychotic events still remains unclear
(reviewed in [320]), albeit a recent study analyzing variations in the
exons and exon–intron boundaries of the ADORA2A gene in
methamphetamine dependent/psychotic patients suggested that the
ADORA2A gene could be a vulnerability factor for the psychotic
consequences of methamphetamine dependence [333].
The anti-convulsant and anti-kindling mechanism of action of
carbamazepine, a drug used primarily in the treatment of epilepsy and
bipolar disorder, seems to include an adenosinergic modulation [334],
basically by an action on A1R [335,336]. Additionally, carbamazepine
treatment induces anupregulation of A1R in brain cells that express low
basal levels of A1R [337] and the protective activity of carbamazepine is
potentiatedusing theadenosine receptor agonistAPNEA, acting through
A1R [338]. Therefore, it is reasonable to suggest that the antimanic
effects of some mood stabilizers might be associated in part with the
effects operated by the adenosine neuromodulation system, mostly
through actions operated through A1R.
4.8. Schizophrenia
Schizophrenia is a neurodevelopmental disorder with both genetic
and environmental components that comprises three distinct symptom
clusters: positive symptoms (delusions, agitation, hallucinations),
negative symptoms (blunted affect, anhedonia) and cognitive dysfunc-
tion (executive function deﬁcits andworkingmemory dysfunction) (for
review see [339]). Currently, schizophrenia is best explained by the
dopamine and glutamate hypotheses. However, adenosine receptors
can control both dopaminergic and glutamatergic systems [69,214], and
its neuromodulation role supports the newly proposed adenosinergic
hypothesis of schizophrenia, which constitute a link between the two
other hypotheses [340].
Several indirect ﬁndings suggest that adenosinergic activity might be
deﬁcient in schizophrenia. Presynaptically, the increased in dopamine
turnover [341] and release [342] in schizophrenia are consistent with a
loss of A1R-mediated inhibitory tonus on the dopaminergic system. A1R
antagonists cause a potentiation of amphetamine-induced locomotion
[343] and dopamine release in the nucleus accumbens [344] while
adenosine receptor agonists display antipsychotic-like proﬁle [345–347].
Evidence of altered adenosinergic activity in schizophrenia includes the
upregulation of striatal A2AR [348], which could be compensatory to low
adenosinergic activity [340], as well as the clinical improvement of
schizophrenic patients with dipyridamole and allopurinol, two pharma-
cological agents enhancing adenosine activity [324,349]. The blockade of
adenosine receptors by caffeinemightexacerbatepositive symptomsand
a reversal of caffeine-induced behaviors is observed by antipsychotics
[345,350]. In addition, theophylline (a non-selective adenosine receptorantagonist) [351], aswell as A2AR knockoutmice have a reduction in the
startle habituation, a measure of sensorimotor gating disrupted in
patients with schizophrenia [352]. Regarding the dopaminergic
involvement in schizophrenia, it is noteworthy that activation of A2AR
reduces the effectiveness of dopaminergic D2 receptor signalling (both
afﬁnity and intracellular effects, see review in [174]), being the probable
mechanism underlying the antipsychotic-like proﬁle of adenosine
agonists [353].
Genetic studies also support the adenosine hypofunction hypothesis
of schizophrenia. A single-nucleotide polymorphismof theA2ARgene on
chromosome 22q12-13 was found to increase schizophrenia suscepti-
bility [354,355]. In addition, studies using a transgenic mouse model
overexpressing adenosine kinase, demonstrated that the decrease in
adenosine levels in the forebrain could lead to the emergence of
behavioral endophenotypes implicated in schizophrenia and abnormal
response to psychostimulants [356]. A functional polymorphism of
adenosine deaminase (G/A genotype) associated with low adenosine
deaminase activity, was also found to be less frequent in schizophrenic
patients [357]. In addition, A1R polymorphismsmay also represent good
candidate markers for schizophrenia research and were found to be
involved in the pathophysiological mechanisms of schizophrenia in
Japanese populations [358].
The adenosinergic hypothesis was further reﬁned by neurodevelop-
mental data showing that A1R can mediate the neurotoxicity in early
stages of brain development, leading to an excessive adenosine release
and to primary brain changes. These events would lead to an adenosine
inhibitory deﬁcit through a partial loss of A1R that may emerge as
reduced control of dopamine activity and increased vulnerability to
excitotoxic glutamate action in the mature brain (reviewed in [359]).
According to the glutamate hypothesis, NMDA receptor blockade
can give rise to behavioral dysfunction and psychotic-like behavior,
while co-agonists of theNMDA receptors, such asD-serine and glycine,
improve cognition andnegative symptoms in schizophrenia [360,361].
A1R and A2AR agonists have both been shown to prevent behavioral
and EEG effects induced by NMDA receptor antagonists [362,363], and
the function ofNMDA receptors can bemodiﬁedby bothA1RandA2AR
[25,36,37,364,365]. Furthermore, both A1R and A2AR control the
evoked release of glutamate in the striatum [35,176]. Conversely, the
activation of the NMDA receptors increases the adenosine tone [366],
while inhibition of NMDA receptors leads to a reduction of adenosine
release [367]. Importantly, the psychostimulant effects of NMDA
receptor antagonists are largely abolished by genetic inactivation or
pharmacological blockade of A2AR [368,369], supporting the idea that
modulation of adenosine receptorsmay rebalance the hypofunction of
NMDA receptors in models of schizophrenia.
Finally, it was observed that the ability of clozapine (an atypical
antipsychotic, and to a lesser extent haloperidol) to induced c-fos
expression is blocked byA2AR antagonists [370] and this antipsychotic
also affected the key pathway of formation of ATP-derived adenosine
acting on A2AR, the ecto-nucleotidase pathway [356].
4.9. Phobia
Fear is an adaptive response to potentially dangerous (external
and internal) stimuli. However, when disproportional in intensity,
chronic, irreversible, or not associatedwith any genuine risk, it may be
symptomatic of a debilitating anxious state (i.e. phobia, panic attacks
or generalized anxiety disorder) [371,372]. Panic and phobic
disorders are the most frequently diagnosed anxiety disorders,
associated with signiﬁcant psychosocial morbidity [373,374].
A strong link between the adenosine modulation system and the
control of fear processing and anxiety is suggested by several types of
studies, namely: i) animal models designed to mimic anxiety traits;
ii) epidemiological studies with caffeine, both in normal subjects and in
patients in anxiety disorders; iii) gene linkage studies in humans
(reviewed in [320,375]). However, the role of adenosine receptors in
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caffeine consumption by phobic patients are rare, especially in
comparison to research on caffeine consumption among patients with
other anxiety disorders like panic disorder. A study from Boulenger and
Uhde [376] showed that panic disorder patients have increased
sensitivity to caffeine and its consumption appears to be more strongly
linked to generalized anxiety symptoms than to 'phobic-anxiety'
symptoms. The work from Uhde [377] also showed that anxiety
symptoms are not made more severe by caffeine consumption in social
phobics and that caffeine consumption in social phobic individuals does
not differ from the general population. In addition, no differences in
electroencephalographic activity of patients with panic disorder versus
control subjects were observed after oral administration of caffeine
[378]. On the other hand, another study reported that caffeine can
induce panic attacks in both panic disorder and social phobic patients
following consumption of a dose of 480 mg [379]. It was also
demonstrated that caffeine ingestion per se does not appear to reduce
fear extinction at least in some speciﬁc phobias, whereas changes in
caffeine consumption, during learning or recall tests, can enhance the
return of fear in spider phobia [380].
Another line of evidence that indicates a possible role for the
adenosinergic system in anxiety-related conditions derives from
polymorphism analysis of the A2AR gene. It was observed that there is
a signiﬁcant association between self-reported anxiety after caffeine
administration and two linked polymorphisms of the A2AR gene, the
1976 CNT and 2592 CNT polymorphisms [354,355]. Likewise polymor-
phisms of the A2AR gene were also observed to be associated with the
incidence of panic disorder and agoraphobia [381–384]. A genetic
variation of the A2AR gene was also found to inﬂuence sympathetic
indicators of anxiety-related disorders in blood-injury phobia, further
supporting a role for the adenosinergic system in the pathogenesis of
anxiety disorders [385].
5. Neuroprotection and neuroregeneration
Current pharmacotherapy of neurodegenerative diseases is focused
on symptomatic relief and eventually on neuroprotective temptative
approaches. These strategies delay neuronal death, but do not consider
the regeneration of damaged neurons. Neuronal survival is necessary,
but not sufﬁcient for complete structural and functional recovery after
injury or after the onset of pathogenic triggers of disease. Thus, besides
neuroprotection, it is crucial to ensure that local environment around
the lesion site has the appropriate conditions for re-innervation of
degenerated regions. Neurotrophic factor-mediated actions and neuro-
genesis are innate self-repair mechanisms of the nervous system,
although limited and inefﬁcient to completely recover all damaged
neurons. We will now brieﬂy summarize the potential for the
involvement of adenosine receptors in neurogenesis and in the
modulation of trophic factor-mediated regenerative effects.
5.1. Interaction with growth factors
There are several actions by which trophic factors could provide
important therapeutic beneﬁts inneurodegenerativediseases, including
their ability to promote survival of speciﬁc neuronal populations
exposed to an injury, i.e. neuroprotection. Neuroprotective effects of
trophic factors are well illustrated by animal studies where these
molecules are administered prior to an insult (e.g. MPP+, 6-OHDA); just
to mention a couple of examples, brain-derived neurotrophic factor
(BDNF) or glial cell line-derived neurotrophic factor (GDNF),
administered after neurotoxins decrease the extension of neuronal
loss [386–394]. A secondmechanism resulting in therapeutic beneﬁts is
the restoration of function, i.e. neuroregeneration. Far beyond their roles
during development, trophic factors are able to regulate axonal and
dendritic outgrowth, de novo synapse formation, cell proliferation and
survival of adult neurons [395–405].The adult mammalian brain is unable to efﬁciently promote
reparative actions, in particular axonal regeneration, mainly due to
the low intrinsic ability of adult neurons to regrowaxons, but alsodue to
the restricted supply of appropriate trophic factors and to the presence
of inhibitory molecules controlling this process [406]. Thus, axonal
damage characteristic of several degenerative conditions often results in
persistent functional deﬁcits. Axonal regrowth can occur by collateral
sprouting from intact neurons into denervated areas or by regenerative
growth of injured neurons to re-establish connectionswith target areas.
Several trophic factors are able to induce this kind of restorative actions,
as well as to interact with effectors, such as cyclic adenosinemonopho-
sphate (cAMP) and overcome inhibitory action induced by growth
inhibitory molecules [407].
Since the discovery of the ability of A2AR to transactivate the main
BDNF receptor, TrkB [408], intense research has focused on the effects of
adenosine on the release and on the short-termeffects of trophic factors
[204,409–412]. Considering the established functional interaction
between A2AR and trophic factors, some authors argue that A2AR
agonists may be beneﬁcial in degenerative conditions (discussed in
[203]). However, to date, there are no studies in pathological conditions,
i.e. in animal models of degenerative diseases to support the idea.
Clearly, the fact that trophic factors aremostly considered to be survival
promoting factors casts someconcern on thepotential harmful effects of
long-term use of A2AR antagonists to manage neurodegenerative
disorders. However, the observation that the consumption of caffeine
(an adenosine receptor antagonist) is not only essentially safe but
provides global beneﬁcial effects in different neurodegenerative
disorders, clearly argues against potential detrimental effects resulting
from long-term consumption of A2AR antagonists and seriously
dampens the physiopathological relevance of this trans-activation
between A2AR and TrkB receptors.
It is also important to emphasize that trophic factors may also be
deleterious rather than only protective or restorative. This is the case
for BDNF, which is synthesized as a precursor protein often involved in
neuronal death. Furthermore, mature BDNF and the precursor protein
activate two different receptors (TrkB and p75), both of them existing
as full-length or truncated forms. The activation of each receptor
isoform by precursor or mature BDNF often results in opposite actions
in terms of cell survival or death [413,414]. And it still remains to be
explored if adenosine receptors (or caffeine consumption) might be
able to inﬂuence the detrimental effects of abnormal signalling by
growth factors. Therefore, it is of utmost importance to clarify the
functional interaction between adenosine and trophic factors in
animal models of degenerative diseases to effectively grasp if the
manipulation of adenosine receptors might be envisaged as a novel
reaparitive strategy based on the control of the action of growth
factors.
5.2. Neurogenesis
Adult neurogenesis, a process bywhich newneurons are generated
from neural stem or progenitor cell populations in limited areas of the
brain [415–420], is indicative of an intrinsic ability of the nervous
system to self-repair, but is limited and unable to reverse the ongoing
neuronal loss charactering neurodegenerative diseases. Both in vitro
and in vivo, newly formed neurons express classical neuronal markers
[421–424] and exhibit morphologic and physiologic characteristics of
intrinsic neurons, such as excitability-related electrophysiologic
properties and formation of functional synaptic connections [423].
Neurogenesis throughout lifemay be important in processes such as
learning and memory [425–427] and changes in neurogenesis have
been associated with neurological diseases. For instance, depression is
causally related with declining neurogenesis in the hippocampus
[428,429]. Accordingly, antidepressant drugs promote de novo adult
neurogenesis and block stress-induced decrease of neurogenesis [430]
andneurogenesis blockade compromises the efﬁcacy of antidepressants
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that neurogenesis is impaired in neurodegenerative diseases, such as
PD, HD and AD [433–438] but is enhanced following stroke [439,440];
curiously, after stroke, a certain degree of recovery is observed in
patients over time.
In normal or disease conditions, neurogenesis involves four general
cellular events: i) proliferation of stem/progenitor cells; ii) migration of
stem/progenitor cells into different areas of the central nervous system;
iii) differentiation into speciﬁc neuronal cell types; iv) integration in the
established neuronal circuitry. Stem/progenitor cells with
undifferentiated self-renewal and multipotent features reside in two
major areas: subventricular zone (SVZ) along the walls of lateral
ventricles [419,441] and the subgranular zone (SGZ) of the dentate
gyrus of the hippocampus [422,442–444]. The newborn neurons
generated in these germinative areas migrate to the olfactory bulb
(OB) [445,446] and to the granule cell layer (GCL) of the dentate gyrus
[421,447], respectively, where they differentiate and incorporate into
the pre-established circuitry.
There is increasing evidence that purinergic signalling pathways
are involved in mammalian adult neurogenesis (for a review see
[448]). Interestingly, there are only few reports on the role of caffeine
in adult neurogenesis [449–451], in spite of several ﬁndings favoring
the potential involvement of adenosine in the process, namely: 1) the
tissue non-speciﬁc form of alkaline phosphatase (TNAP), an enzyme
which hydrolyzes extracellular nucleotides to nucleosides, including
adenosine from extracellular ATP [452] has a selective localization in
the SVZ, including its extension into the OB [453], in spite of the lack of
activity in the neurogenic dentate gyrus of the hippocampus [454];
furthermore, TNAP co-localize with a marker for immature and
migrating neurons and cells of the adult SVZ, doublecortin [453]; 2)
ecto-5′-nucleotidase, the major enzyme involved in the extracellular
formation of adenosine [455] is present in the adult OB and is involved
in lesion-induced sprouting within the adult dentate gyrus [146];
3) functional adenosine receptors were identiﬁed in neurosphere cells
(in vitro cultured neuron stem cell aggregates) cultured from the adult
mouse SVZ [456]; these cells predominantly express A1R and A2BR
and A1R agonists (but not A2AR agonists), are able to increase the
proliferation of these cells in a time- and concentration-manner [457];
4) the complexity of behavioral and biochemical effects of adenosine
in the central nervous system; for instance, caffeine inﬂuences
locomotor activity, which has been shown to increase neurogenesis
in the dentate gyrus [458]; at higher doses, caffeine also inﬂuences
anxiety and stress, both associated with depressed adult neurogenesis
[459,460]; indirectly, the vasocontrictive effects of caffeine could alter
the vascular neurogenic niche in the brain [461] and modify adult
neurogenesis; adenosine signalling has been shown to potentiate
BDNF signalling in the hippocampus, which has been established
as an important factor modulating the survival of adult-born
hippocampal neurons and implicated in exercise-induced survival of
adult-born neurons [462]; 5) caffeine does not affect the differentiation
or the long-term survival of precursor cells, but inﬂuences their
proliferation in the adult hippocampus in a time- and dose-dependent
manner: extended moderate-high doses of caffeine depress (20–25%)
proliferation in the dentate gyrus and higher doses increase (50%)
proliferation [449,451].
Surprisingly, very little is known concerning adenosine effects upon
adult neurogenesis. This apparent lack of interest may be due to the
strong evidence for the involvement of nucleotides in the control of
neurogenesis.More integrative experimental design, analyzingmultiple
and interactivemechanismsmay unmask a possible role of adenosine in
adult neurogenesis. Wentz and Magavi [451] proposed that caffeine
may be considered a slow-onset modiﬁer of neurogenesis, and that its
contribution is probably related to habituation or adaptation to caffeine,
which presumably induces compensatory changes in systems where it
inﬂuences biochemical effects and alters activity, such as cortical,
thalamic and striatal neurons.It is also possible that homeostasis requires a limited supply of the
factors for sustained adult neurogenesis.More speciﬁcally, considering
the ﬁrst results on the inhibitory effect of neuroinﬂammation upon
neurogenesis [463,464], adenosine involvement in the control of
neuroinﬂammation (and in particular, A2AR-mediated control of
neuroinﬂammation) could be a potential mechanism by which
neurogenesis is suppressed in neurodegenerative diseases. However,
more recent studies conceive neuroinﬂammation as having a dual role
in neurogenesis [465,466] and, thus, further studies are needed in
order to test this hypothesis.
6. Concluding remarks
This more detailed review on the available evidence relating the
adenosinergic system and different neurological and psychiatric
disorders highlights the potential of manipulating the adenosine
receptor neuromodulation system as a novel strategy to manage brain
disorders (Fig. 1). However, in spite of this potential interest, it is also
clear that a long road lies ahead to attempt conﬁrming the
effectiveness of manipulating this system to obtain some clinical
beneﬁt in the management of brain disorders. There are obvious and
immediate questions related to the how and when to manipulate the
adenosine system.
As a way of conclusion there seem to be a parallel beneﬁt of
manipulating both A1R and A2AR. Overall, it seems that A1R effectively
act as a hurdle contributing to increase the threshold to initiate
neurodegenerative processes and the relevance of A1R seems to
decrease upon continuous activation. Since A1R function has not yet
been shown to revert or arrest ongoing brain damage, it is expectable
that bolstering the activation of A1R will be of little interest to control
the death of brain tissue once the insult has begun its damaging effects.
However, since all neurodegenerative processes are evolving condi-
tions, targeting A1R activation may be of real interest if one considers
that it may control the spreading of neurodegeneration; likewise,
bolstering A1R activation may also be of interest when the time-span
between the initial impact of the insult and the initiation of the
neurodegenerative process is large, i.e. when the initial damaging
insults sets a cascade of modiﬁcations that allow for compensatory
mechanisms to delay more permanent and irreversible damage. The
work of Detlev Boison has largely set the stage to provide a tentative
answer to the question of how to manipulate A1R function: instead of
using A1R agonists (which cause profound peripheral effects), it seems
more effective to control the activation of A1R by enhancing the
endogenous adenosine levels through inhibition of the activity of
adenosine kinase. Albeit promising, the mechanisms, long-term con-
sequences and potential drawbacks of this strategy still have to be
explored. Thus, it is still not known how the inhibition of adenosine
kinase changes the extracellular levels of adenosine (in the brain
parenchyma and also in synapses), if it causes long-term changes in
adenosine metabolism (as occurs for long-term effects related with the
continuous activation of A1Rwith A1R agonists) and if it causes changes
in the expression, density and subcellular localization of both A1R and
A2AR. Also, given that adenosine metabolism takes place intracellularly
and the neuroprotective actions of adenosine have been shown to
depend on the action of extracellular adenosine on A1R, there is a clear
need to better comprehend the transport of adenosine across cell
membranes through nucleoside transporters, which may become an
eventuallymore tempting target that adenosine kinase. There is also the
question of providing a mechanistic rationale for this A1R-mediated
neuroprotective effect of adenosine kinase inhibitor. Thus, it seems an
established fact that bolstering A1R affords neuroprotection; however,
the mechanism(s) underlying A1R-induced neuroprotection is still
unclear (see [84] for a detailed discussion). Finally, the possible negative
impact of manipulating adenosine kinase still remains to be explored
(see [356]). But the main message here is that the inhibition of
adenosine kinase affords an evident beneﬁt in experimental models of
Fig. 1. Proposed impact of different manipulations of the adenosine neuromodulation system to control both neurological and psychiatric disorders.
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concept for a similar neuroprotective potential of adenosine kinase
inhibitors in other brain disorders still remains to be explored.
Furthermore, in relation to the translational potential of this strategy,
there is the clear need to explore the biochemistry of adenosine kinase
and the neurochemical impact of its inhibition in human tissue,
especially in view of the existence of polymorphisms of adenosine
kinase in humans thatmay be associatedwith different susceptibility to
brain disorders.
The other ‘competing’ view on the impact of the adenosine
neuromodulation system on brain damage is centered on the role of
A2AR, namely on the ability of A2ARblockade to attenuate the burdenof
most brain disorders (Fig. 1). The last years havewitnessed a substantial
increase in the number of reports documenting the ability of the
pharmacological or genetic blockade of A2AR to attenuate brain damage
caused by different insults. However, the underlying mechanisms are
still to be unravelled, and there seems to be nearly as many possible
mechanisms as researchers dedicated to the subject (see [84] for a
detaileddiscussionof putativemechanismsoperatedbyA2AR to control
brain damage). It should also be noted that there are some reports
suggesting that in some particular models it seems to be the activation
rather than the blockade of A2AR that seems to afford neuroprotection.
This mostly occurs in models involving the degeneration of striatal
neurons; this strengthens the idea that postsynaptic A2AR in striatal
medium spiny neurons are clearly an ‘aberrant’ population of A2AR:
these receptors make the striatum the brain region with the largest
density of A2AR, but these A2AR display properties often opposite of
these displayed by other A2AR (e.g. [369]) and, therefore, should not be
used as models of A2AR functioning in the brain but solely as models of
what they are, i.e. controllers of signal processing in medium spiny
neuron that are not related to neuroprotection. In view of our
surprisingly scarce knowledge on the physiological role(s) of A2AR in
the central nervous system, it is not surprising thatwe are still at a stage
of phenomenological rather than mechanistic understanding of the
impact of A2AR on the complex processes of brain dysfunction and
evolving damage associated with different brain disorders. The role ofA2AR in the control of brain damage is further complicated by the
plasticity of its expression and its promiscuity in terms of recruitment of
intracellular signalling pathways, which leads to the hypothesis that the
newly expressed A2AR upon brain insults (see [8] for a review on the
changes of A2AR expression and density upon brain damage) may fulﬁl
roles different from constitutively expressed A2AR. And certainly
without this fundamental supportive information, we currently lack a
rationale to logically sustain any proposal on when and how to
manipulate A2AR function to attempt controlling the demise(s) of
brain disorders. There is another question of particular importance
when considering the translational interest of A2AR: we still know
surprisingly little about A2AR in the human brain, either in terms of its
pharmacological properties, localization, function(s) and modiﬁcations
upon brain disorders. And this is crucial information to evaluate the
extent to which animal models are representative of the role of this
receptor in the human brain.
This summary, the potential and current uncertainties related with
the interest of manipulating either A1R or A2AR, leads to an obvious
question related to the role of adenosine (the actual endogenous
ligand) in the control of brain disorders. Clearly the arguments that
both A1R activation and A2AR blockade may afford beneﬁts in the
control of brain disorders means that adenosine plays a double role in
the control of brain disorders. There are two parallel groups of
questions that need to be considered. First, from the intervention point
of view, the obvious suggestion should be to link both strategies in a
common framework. This would mean that the most powerful
neuroprotective strategy targeting the adenosine neuromodulation
system should be based on a combined inhibition of adenosine kinase
with a blockade of A2AR, as previously proposed [40]. But this should
require prior investigation of the impact of A2AR blockade on
adenosine metabolism (i.e. does it affect the expression or activity of
adenosine kinase or of adenosine transport?) and, conversely, on the
impact of the inhibition of adenosine kinase on the expression, density,
localization, transducing systems and functions of A2AR. The second
major and most fundamental question is related to our current lack of
knowledge on the metabolism of adenosine: thus questions such as
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adenosine remain unanswered and the subcellular localization of all
the players controlling these extracellular adenosine levels in brain
tissue also remains unexplored. In fact, knowingwhen,where andhow
the extracellular levels of adenosine are changing in different deﬁnable
extracellular domains in the brain parenchyma (synaptic, neuronal-
astrocytic, astrocytic-vascular or astrocytic-microglia domains) aswell
as in endothelial cells forming brain barriers or in inﬁltrating myeloid
cells, seems of fundamental important to allow predicting the impact
of manipulating the adenosine modulation system.
The last concluding remark is related to the knowledge gathered
from the impact of caffeine consumption on brain disorders. From
the superﬁcial point of view, there is an (apparently) easy conclusion
that can be drawn: the chronic consumption of moderate doses of
caffeine seems to afford a prophylactic beneﬁt since it decreases the
incidence of most brain disorders (Fig. 1). The situations seem
clearer in animal models (see [250]) than in humans, where most
studies have evaluated the consumption of coffee, which is certainly
rich in caffeine but where numerous other active compounds are
present. The effects of caffeine have largely been interpreted as
resulting from an effect on the adenosine neuromodulation system.
In fact, the neuroprotective effects of caffeine seem to be mimicked
by A2AR blockade in different animal models of brain disorders
(reviewed in [250]). However, the observation that either chronic
caffeine consumption or A2AR blockade afford neuroprotection
cannot be taken as a demonstration that chronic caffeine intake is
acting through A2AR blockade to afford neuroprotection and the fact
that the two manipulations cause the same overall effect makes it
particularly difﬁcult to actually demonstrate a causal link. The
question of how caffeine is acting to afford neuroprotection is
particularly tricky to discuss since we still do not know the actual
levels of caffeine in the brain parenchyma upon its chronic
consumption (see [467] for a discussion on the available data) nor
do we know how the chronic caffeine consumption affects the
expression density and function of A1R and A2AR nor the
extracellular metabolism of adenosine. Finally, it should be kept in
mind that, although the available evidence supports that adenosine
receptors should be the main targets of caffeine [4,8], there is
evidence that caffeine can affect different other molecular targets
with different efﬁciency such as phosphodiesterases, GABA-A
receptors and controllers of intracellular calcium stores, just to
name a few. And most of these alternative targets are actually
constituted by different isoforms and it is currently unknown if
caffeine differently affects each of the isoforms, and whether they
play different roles in the control of brain damage. This question is
particularly pertinent for humans, where we simply lack reliable
information on the pharmacodynamic of caffeine in brain tissue.
Thus, although there is a tentative global impression that the
prophylactic effects of caffeine can be taken as evidence for a role of
the adenosine neuromodulation system in the control of brain
disorders there still seems to be several open question to ﬁrmly
secure this conclusion.
The impact of caffeine on brain disorders also opens another
pertinent question related to the usefulness of targeting the adenosine
neuromodulation system to manage brain disorders. Both the
consumption of caffeine as well as the blockade of A2AR have proved
efﬁcient when administered before the insults triggering brain
damage. Thus, they have been suggested to afford a prophylactic
beneﬁt; they have not been broadly shown to provide a beneﬁt once
the damage is progressing, i.e. they have not been shown to display
therapeutic effects. To a large extent, the same occurs for A1R, which
manipulation only affects brain damage if carried out in the temporal
vicinity of the perturbing insult, albeit the manipulation of adenosine
kinase was shown to actual revert the phenotype in an animal model
of epilepsy [131]. Thus, it should be carefully evaluated if the proposal
to target the adenosine neuromodulation system to manage braindisorders should focus on prophylaxis or also on treatment of these
brain conditions.
In summary, the current status of knowledge on the potential
interest of the adenosine neuromodulation system is rather exciting.
Albeit there are several open questions that demand careful attention,
the general impression is that there is a great potential to further
explore this system to develop novel strategies to control both
neurological and psychiatric brain disorders.Acknowledgements
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